Success Metrics

Clinical Success Rate
79.4%

Based on 108 completed trials

Completion Rate
79%(108/136)
Active Trials
13(6%)
Results Posted
28%(30 trials)
Terminated
28(13%)

Phase Distribution

Ph phase_1
29
14%
Ph not_applicable
23
11%
Ph phase_2
106
50%
Ph early_phase_1
2
1%
Ph phase_4
1
0%
Ph phase_3
41
19%

Phase Distribution

31

Early Stage

106

Mid Stage

42

Late Stage

Phase Distribution202 total trials
Early Phase 1First-in-human
2(1.0%)
Phase 1Safety & dosage
29(14.4%)
Phase 2Efficacy & side effects
106(52.5%)
Phase 3Large-scale testing
41(20.3%)
Phase 4Post-market surveillance
1(0.5%)
N/ANon-phased studies
23(11.4%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

74.5%

108 of 145 finished

Non-Completion Rate

25.5%

37 ended early

Currently Active

13

trials recruiting

Total Trials

211

all time

Status Distribution
Active(15)
Completed(108)
Terminated(37)
Other(51)

Detailed Status

Completed108
unknown50
Terminated28
Recruiting10
Withdrawn9
Active, not recruiting3

Development Timeline

Analytics

Development Status

Total Trials
211
Active
13
Success Rate
79.4%
Most Advanced
Phase 4

Trials by Phase

Early Phase 12 (1.0%)
Phase 129 (14.4%)
Phase 2106 (52.5%)
Phase 341 (20.3%)
Phase 41 (0.5%)
N/A23 (11.4%)

Trials by Status

not_yet_recruiting21%
recruiting105%
withdrawn94%
suspended10%
unknown5024%
completed10851%
terminated2813%
active_not_recruiting31%

Recent Activity

Clinical Trials (211)

Showing 20 of 211 trialsScroll for more
NCT07729670Phase 2

Multimodal Ablation Combined With Perioperative Tislelizumab and Chemotherapy for Resectable II-IIIB NSCLC

Not Yet Recruiting
NCT07089199Phase 2

Tislelizumab Combined With Anlotinib and Nab-paclitaxel in III Resectable Non-small Cell Lung Cancer : A Prospective, Single-Arm, Phase II Study

Recruiting
NCT07589972Not Applicable

Neoadjuvant Trastuzumab, Pertuzumab Plus Metronomic Vinorelbine for Elderly HER2-Positive Breast Cancer

Not Yet Recruiting
NCT07590570

The Association of Lunula Status With the Efficacy and Safety of Neoadjuvant Therapy in Breast Cancer

Active Not Recruiting
NCT00872625Phase 1

Radiation Therapy and Docetaxel Followed by Standard Therapy in Treating Women With Breast Cancer

Completed
NCT07103395Phase 2

A Study Evaluating Neoadjuvant Chemotherapy, Concurrent Chemoradiotherapy Combined With Dual Immune Checkpoint Blockade in Patients With Locally Advanced Non-Small Cell Lung Cancer

Recruiting
NCT07038122Not Applicable

Reducing the Resection Range After Neoadjuvant Therapy for Locally Advanced Upper Rectal and Rectosigmoid Junction Cancers

Active Not Recruiting
NCT06734702Phase 3

Neoadjuvant Immunotherapy Plus Chemotherapy Followed by Concurrent Chemoradiotherapy and Consolidative Immunotherapy for Locally Advanced Non-small Cell Lung Cancer

Recruiting
NCT00354393Phase 2

Combination Chemotherapy With or Without Surgery & Chemoradiotherapy in Patients With Malignant Pleural Mesothelioma

Completed
NCT00544414Phase 2

Chemotherapy Followed by Surgery, Chemotherapy, and Radiation Therapy in Treating Patients With Locally Advanced Head And Neck Cancer

Completed
NCT06792149

Prediction of Drug Response in Gastric Cancer Based on 3D Bioprinting

Recruiting
NCT06642428Not Applicable

Effect of Vitamin D Supplementation on the Efficacy and Adverse Effects of Neoadjuvant Therapy in Patients with Breast Cancer

Recruiting
NCT06385288Not Applicable

Blood and Tissue Extraction for Immunological Examinations During Neoadjuvant Therapy of Soft Tissue Sarcomas

Recruiting
NCT06630481

Long-term Survival Outcomes According to the Pathologic Response After Neoadjuvant Treatment in PDAC and the Fate of the Patients with Good CAP Grade

Completed
NCT04085250Phase 2

Study of Nivolumab for Non-Small Cell Lung Cancer (Stage III) Following Neoadjuvant Chemotherapy Plus Nivolumab and Definitive Concurrent Chemoradiation Therapy

Active Not Recruiting
NCT00482755Phase 2

Sunitinib in Treating Patients With Newly Diagnosed Stage II or Stage III Breast Cancer That Can Be Removed by Surgery

Completed
NCT05173272Phase 3

Induction Chemotherapy Combined With Immunotherapy Followed by Concurrent Chemoradiation in Advanced Cervical Cancer

Recruiting
NCT06151379

Muscle Parameters and Pathological Response in Breast Cancer Patients

Completed
NCT06003673Phase 4

A Clinical Study of Tislelizumab Combined With TACE and Lenvatinib in the Neoadjuvant Treatment of Resectable HCC

Unknown
NCT06080620Not Applicable

The Choice of Treatment Methods and Efficacy of LABC

Recruiting

Drug Details

Intervention Type
DRUG
Total Trials
211